Condition
Staphylococcal Bacteremia and Endocarditis
Staphylococcal bacteremia means Staphylococcus bacteria have entered the bloodstream, and endocarditis is an infection of the heart's inner lining or valves. The strongest evidence is for daptomycin, an intravenous antibiotic: in 246 people, treatment success at 42 days was similar to standard therapy, and adding a second antibiotic did not improve outcomes. It matched standard care rather than beating it, and the endocarditis results covered right-sided infections.
Sources: PMID 16914701
- Updated
- How we grade
- 41 studies cited
- Supplements studied
- 0
- Medicines and peptides
- 1
- Graded outcomes
- 2
No supplement studies yetWe haven’t found supplement studies for Staphylococcal Bacteremia and Endocarditis. The medicines and peptides studied for it are listed below.
Prescription medicines and peptides studied, for context
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Bacteremia/Endocarditis Cure Fowler NEJM 2006 (n=246): Treatment success at 42 days 44.2% vs 41.7% standard therapy (noninferiority met). 6 mg/kg IV daily. Effective for both MRSA and MSSA right-sided endocarditis. CAMERA2 trial: Adding beta-lactam did not improve outcomes vs daptomycin alone. | NoneNo effect | 17 studies | ||||
Studies that measured bacteremia/endocarditis cure | ||||||
| Nephrotoxicity vs Standard Therapy Fowler NEJM 2006: Clinically significant renal dysfunction 11.0% daptomycin vs 26.3% standard therapy (vancomycin+gentamicin), P=0.004. Significant renal-sparing advantage. Does not require renal dose adjustment until CrCl <30 mL/min. | Improves (the measure goes down) | Large effect | 16 studies | |||
Key findings
- Bacteremia/Endocarditis Cure
- Nephrotoxicity vs Standard TherapyImproves (the measure goes down)
Studies cited
41 studies from PubMed
- Daptomycin-induced pulmonary eosinophilia: early identification of antibiotic side effects.
- Daptomycin treatment for persistent bacteremia in a pediatric solid organ transplant recipient: Case report and literature review.
- Daptomycin Dosage Optimization in Renal Impairment Using Model-Informed Precision Dosing.
- Lipidation Engineering in Daptomycin Biosynthesis.
- Daptomycin-Induced Eosinophilic Pneumonia: A Case Report and Systematic Review.
- Daptomycin for the treatment of acute bacterial meningitis: A narrative review.
- Daptomycin as an option for lock therapy: a systematic literature review.
- Efficacy and safety of daptomycin in Japanese pediatric participants with complicated skin and soft tissue infections or bacteremia caused by gram-positive cocci
- Daptomycin synergistic properties from in vitro and in vivo studies: a systematic review.
- Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: A randomized clinical trial
- Efficacy and safety of daptomycin: systematic review and meta-analysis
- Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment.
- Daptomycin for the treatment of Staphylococcus aureus infections complicated by septic pulmonary emboli.
- Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review.
- Daptomycin for complicated skin infections: a randomized trial
- Daptomycin-Phosphatidylglycerol Domains in Lipid Membranes.
- Possible Hepatotoxicity Associated With Daptomycin: A Case Report and Literature Review.
- Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.
- An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection
- Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience.
- Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: A review of the available evidence.
- Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis.
- Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: an open-label, multicentre, randomized phase IIIb trial
- Safety of daptomycin in patients completing more than 14 days of therapy: results from the Cubicin® Outcomes Registry and experience.
- Daptomycin: a review of properties, clinical use, drug delivery and resistance.
- Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin
- Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies.
- Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis.
- Daptomycin: a review 4 years after first approval.
- Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia
- Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
- The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
- Update on daptomycin: the first approved lipopeptide antibiotic.
- [Daptomycin, the first cydal antibiotic of a new class active against Gram positive pathogens].
- Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
- Daptomycin: a novel cyclic lipopeptide antimicrobial.
- Antimicrobial update: Daptomycin.
- Natural products to drugs: daptomycin and related lipopeptide antibiotics.
- The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections
- Daptomycin - a novel antibiotic against Gram-positive pathogens.
- Daptomycin: a cyclic lipopeptide antimicrobial agent.